RadNet (NASDAQ: RDNT) and Bio-Reference Laboratories (NASDAQ:BRLI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.
This table compares RadNet and Bio-Reference Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
46.5% of RadNet shares are held by institutional investors. 9.4% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares RadNet and Bio-Reference Laboratories’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|RadNet||$897.16 million||0.42||$111.45 million||$0.20||39.75|
RadNet has higher revenue and earnings than Bio-Reference Laboratories.
This is a summary of current ratings and recommmendations for RadNet and Bio-Reference Laboratories, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
RadNet presently has a consensus target price of $8.00, indicating a potential upside of 0.63%. Given RadNet’s higher possible upside, research analysts plainly believe RadNet is more favorable than Bio-Reference Laboratories.
RadNet beats Bio-Reference Laboratories on 6 of the 8 factors compared between the two stocks.
RadNet Company Profile
RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.
Bio-Reference Laboratories Company Profile
Bio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.
Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.